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In 2003, families were described with a rare, autosomal dominant form of familial hypercholesterolemia 
due to gain of function mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9) (1). 
Subsequent studies demonstrated that PCSK9 is secreted from liver and accelerates degradation of LDL 
receptors (2,3).  Heterozygosity for PCSK9 null mutations in 2.6% of African-Americans was found to be 
associated with 28% reduction in LDL cholesterol (LDL-C) and an 88% reduction in CAD risk (4).  These 
findings stimulated intense interest in PCSK9 as a pharmaceutical target.  In this issue of Trends in 
Cardiovascular Medicine, Desai and Sabatine thoroughly review recent and ongoing trials of three 
monoclonal antibodies that disrupt PSCK9 binding to LDL receptors, leading to marked reductions in 
LDL-C (5).  As detailed in their review, evolocumab (AMG145), alirocumab (SAR236553/REGN727), and 
bococizumab (RN316) given every 2-4 weeks, reduced LDL-C up to 75% in patients on statin therapy as 
compared to statin therapy alone, up to 51% in statin intolerant patients and other patients not in statin 
therapy, and up to 55% in patients with heterozygous familial hypercholesterolemia, most of whom 
were on statin therapy.   Evolocumab reduced LDL-C up to 31% in patients with homozygous familial 
hypercholesterolemia, although there was no effect in LDL receptor-negative patients. Ongoing 
cardiovascular outcome trials that will rigorously test the ability of these agents to reduce major adverse 
cardiovascular events in high risk patients are also described.  
PCSK9 is secretory serine endoprotease (6).  Pro-PCSK9 is autocatalytically cleaved during its maturation 
in the golgi, but the prodomain remains tightly bound after secretion, precluding further catalytic 
activity (6).  Effects of PCSK9 on LDL-C clearance thus do not depend on its protease activity.  Rather, 
circulating PCSK9 binds the first epidermal growth factor-like repeat domain in the extracellular portion 
of the LDL receptor (6).  Endocytosed LDL receptor is normally recycled back to the plasma membrane, 
but PCSK9 locks the receptor in an open conformation that targets it to lysosomes for degradation (6).  
The PCSK9-binding monoclonal antibodies under development disrupt this interaction and prevent LDL 
receptor degradation.  Up to 40% of circulating PCSK9 is bound to LDL particles via a specific interaction 
with apoB100 (6,7).  Only free, unbound PCKS9 down regulates LDL receptors (6).  PCSK9 does not bind 
VLDL or chylomicrons, suggesting that the interaction site may be unmasked during the intravascular 
remodeling of apoB100-containing lipoproteins (6,7).  There is also a separate, intracellular pathway in 
which nascent PCSK9 binds LDL receptors and directs them from trans-golgi to lysosomes (8).  However 
the extracellular pathway is the predominant mechanism of PCSK9-mediated LDL receptor degradation 
in vivo.  Statins deplete intracellular cholesterol and upregulate LDL receptor transcription through 
sterol regulatory element-binding protein-2 (SREBP-2) (9).  As PCSK9 transcription is also regulated by 
SREBP-2, PCSK9 levels are increased with statin therapy, which attenuates statins’ LDL-C lowering effects 
(9).  Consistent with this, PCSK9 knockout mice exhibit an exaggerated LDL-C response to statin 
treatment (10). 
Beyond its role in reducing LDL receptor levels, little is known about the biology of PCSK9.  Its expression 
is highest in liver, and lower in kidney, intestine, brain, and lung (11).  Evolocumab lowers lipoprotein(a) 
up to 30%, an effect also seen with other PCSK9 inhibitors (5).  Statins do not decrease lipoprotein(a) 
and the LDL receptor is not thought to be involved in lipoprotein(a) clearance (12).  So the mechanism of 
lipoprotein(a) lowering is not clear.  PCSK9 inhibitors cause modest decreases in triglycerides (13).  Some 
of this may reflect LDL receptor-dependent clearance of apoB containing remnant particles.  However, 
decreased production of triglyceride-rich lipoproteins and upregulation of VLDL receptors may also 
contribute to the triglyceride lowering (7,14).  VLDL receptor expression is increased in visceral adipose 
tissue of PCSK9 null mice, leading to an 80% increase in visceral adiposity (15).  Intracellular degradation 
of apolipoprotein receptor 2 (ApoER2) is increased by PCSK9 (14).  There is evidence that PCSK9 
regulation of ApoER2 modulates neuronal apoptosis (16).   PCSK9 has been shown to mediate 
degradation of LDL receptor-related protein-1 (LRP1) (14).  LRP1 is widely expressed and has been 
implicated in inflammation and atherosclerosis.  Other potential PCSK9 targets include the endothelial 
sodium channel (ENaC) and the hepatic receptor for hepatitis C virus, CD81 (7,14).  The decrease in 
lipoprotein(a) with PCSK9 inhibitors may contribute to improved cardiovascular outcomes.  However the 
implications of most of these observations for PCSK9 inhibitor therapy are unknown.  Published trials of 
PCSK9 inhibitors have generally found adverse events, other than minor injection site reactions, to be 
comparable between groups (5).  Moreover, the description of a few individuals in apparent normal 
health with undetectable circulating PCSK9 due to PCSK9 null mutations and LCL-C levels as low as 14 
mg/dL offers some reassurance that PCSK9 inhibitors will not have serious on-target side effects (17).  
Ongoing long term trials of PCSK9 inhibitors and additional basic research on PCSK9 biology will provide 
important information on long term safety. 
A specific concern with antibody-based therapies is immune reactions.  These are much less likely with 
humanized and fully human antibodies, but can still occur (18).  Most common are development of anti-
drug antibodies, which in some cases can be associated with loss of therapeutic efficacy.  For example, 
28% of rheumatoid arthritis patients treated with adalimumab, a fully human antibody targeting tumor 
necrosis factor, developed anti-adalimumab antibodies over a three year period and these antibodies 
were associated with lower drug levels and decreased of therapeutic efficacy (19).   Anti-evolocumab 
antibodies developed in 2/901 patients in one 52 week trial (13).  In neither of these patients were the 
antibodies associated with loss of efficacy.  More serious immune reactions can also occur.  One patient 
on alirocumab developed leukocytoclastic vasculitis that responded to steroids and drug discontinuation 
(18).  Large, current trials of PCSK9 inhibitors should clarify the extent to which immune reactions are a 
concern. 
A recent post-hoc analysis of patients treated with alirocumab for a mean of 65 weeks found a 54% 
reduction of treatment emergent cardiovascular events (20).  If ongoing trials demonstrate improved 
cardiovascular outcomes and good safety, as seems likely, patients with familial hypercholesterolemia 
and other LDL hyperlipidemias inadequately responsive to maximal statin therapy will be strong 
candidates for addition of anti-PCSK9 therapy.   As PCSK9 inhibitors have shown favorable tolerability 
versus ezitimibe in statin-intolerant patients, this group may also benefit (21).  As noted by Desai and 
Sabatine, it is also possible that lowering LCL-C with PCSK9 inhibitors to levels below those 
recommended in current guidelines may offer additional benefit to very high risk patients (5). However 
this will need to be demonstrated in clinical trials.  A trial of PCSK9 inhibitors in patients with advanced 
renal disease, a population in which the benefits of statins are unclear, would also be worthwhile (22).  
Overall, monoclonal antibodies targeting PCSK9 are a promising new therapy for LDL hyperlipidemia, 
and results of ongoing cardiovascular outcome trials are eagerly awaited. 
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